The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...
The AFIC process is intended to help FDA identify any potential safety concerns associated with animal food ingredients, provide information to the public, request input on animal food ingredients ...